The estimated Net Worth of Matt Davidson is at least $10.9 Milione dollars as of 5 September 2019. Matt Davidson owns over 19,314 units of Verrica Pharmaceuticals Inc stock worth over $4,933,425 and over the last 6 years Matt sold VRCA stock worth over $5,988,485.
Matt has made over 55 trades of the Verrica Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Matt sold 19,314 units of VRCA stock worth $210,329 on 5 September 2019.
The largest trade Matt's ever made was selling 33,521 units of Verrica Pharmaceuticals Inc stock on 28 June 2019 worth over $389,849. On average, Matt trades about 9,955 units every 5 days since 2018. As of 5 September 2019 Matt still owns at least 2,556,179 units of Verrica Pharmaceuticals Inc stock.
You can see the complete history of Matt Davidson stock trades at the bottom of the page.
Matt's mailing address filed with the SEC is C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER, PA, 19380.
Over the last 6 years, insiders at Verrica Pharmaceuticals Inc have traded over $8,200,904 worth of Verrica Pharmaceuticals Inc stock and bought 11,305,854 units worth $62,586,502 . The most active insiders traders include Advisors Llcperceptive Life..., Paul B Manning e John A Iii Stalfort. On average, Verrica Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $213,456. The most recent stock trade was executed by Christopher G. Hayes on 26 August 2024, trading 35,713 units of VRCA stock currently worth $93,211.
verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.
Verrica Pharmaceuticals Inc executives and other stock owners filed with the SEC include: